---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284926520.md"
description: "GoodRx shares are trading higher. The company announced it is providing access to self-pay pricing for Novo Nordisk's Ozempic pill for Type 2 Diabetes Patients."
datetime: "2026-05-01T17:40:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284926520.md)
  - [en](https://longbridge.com/en/news/284926520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284926520.md)
---

# 

GoodRx shares are trading higher. The company announced it is providing access to self-pay pricing for Novo Nordisk's Ozempic pill for Type 2 Diabetes Patients.

### Related Stocks

- [GDRX.US](https://longbridge.com/en/quote/GDRX.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)

## Related News & Research

- [Novo Nordisk says ESSENCE trial shows semaglutide maintains favorable liver safety in MASH](https://longbridge.com/en/news/286908322.md)
- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)
- [CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs](https://longbridge.com/en/news/286925029.md)
- [Novo’s CEO champions “record-breaking start” for Wegovy pill in US market](https://longbridge.com/en/news/285719519.md)